within Pharmacolibrary.Drugs.R_RespiratorySystem.R03D_OtherSystemicDrugsForObstructiveAirwayDiseases.R03DA08_Bamifylline;

model Bamifylline
  extends Pharmacolibrary.Drugs.ATC.R.R03DA08;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>R03DA08</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Bamifylline is a xanthine derivative that acts as a selective adenosine A1 receptor antagonist and has bronchodilator properties. It has been investigated for use in the treatment of asthma and chronic obstructive pulmonary disease (COPD), but it is not currently approved or in widespread clinical use.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for an average healthy adult following oral administration.</p><h4>References</h4><ol><li><p>Schiantarelli, P, et al., &amp; Rondelli, I (1989). Evidence of pulmonary tropism of bamifylline and its main active metabolite. <i>Arzneimittel-Forschung</i> 39(2) 215–219. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2730690/&quot;>https://pubmed.ncbi.nlm.nih.gov/2730690</a></p></li><li><p>Dodion, L, &amp; Aylward, M (1978). Metabolic and pharmacokinetic studies on Bamifylline. A review. <i>Revue de l&#x27;Institut d&#x27;hygiene des mines</i> 33(4) 204–210. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/552145/&quot;>https://pubmed.ncbi.nlm.nih.gov/552145</a></p></li><li><p>Pulido, E, et al., &amp; Battistoni, C (1989). Treatment of patients with chronic airways obstruction: a controlled study with bamyphylline. <i>Pharmatherapeutica</i> 5(6) 416–422. PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/2687897/&quot;>https://pubmed.ncbi.nlm.nih.gov/2687897</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Bamifylline;
